15
Apr
2016

Medivation Stiffs Sanofi, IMS on Drug Spending, & Billionaire Worship

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Pfizer Grabs Metsera, Merck Delivers Oral PCSK9, & Kura Wins 1st FDA OK
Novo-Pfizer Bidding War, BillionToOne IPO, & FDA Turmoil
Novartis Acquires Avidity for $12B, Novo Stiff-Arms Pfizer & Intellia Woes
Takeda Bets on Innovent, NewLimit Lures Lilly, & Merck Makes in America